Lidocaine Infusions Beneficial for Refractory Chronic Migraine
Lidocaine infusions seem beneficial for refractory chronic migraine.
Lidocaine infusions seem beneficial for refractory chronic migraine.
The approval was based on data from a phase 3 trial that assessed Qelbree in adults 18 to 65 years of age with ADHD.
Researchers sought to assess the change in blood pressure in patients with MS treated with ATZ and prior HDMP treatment compared with patients receiving HDMP only for acute relapse.
For patients with moderate-to-severe asthma, as-needed use of a fixed combination of albuterol and budesonide is associated with a lower risk for severe asthma exacerbations compared with as-needed use of albuterol alone.
Researchers sought to assess the short-term benefit and risk of ticagrelor with aspirin in patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack.
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Sulthiame (STM) appears to be safe and effective for the treatment of obstructive sleep apnea.
Tenth version recommends nirmatrelvir/ritonavir in patients with confirmed COVID-19 who have highest risk for hospitalization.
In a systematic review and meta-analysis, researchers compared and evaluated the effect differences of multiple acupuncture therapies for patients with primary insomnia.